<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619302</url>
  </required_header>
  <id_info>
    <org_study_id>2022A012856</org_study_id>
    <nct_id>NCT05619302</nct_id>
  </id_info>
  <brief_title>Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis</brief_title>
  <official_title>Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of our pilot study is to determine whether fibrosis in the heart can be&#xD;
      measured with [68Ga]CBP8, a positron emission tomography (PET) probe, using PET/magnetic&#xD;
      resonance imaging (MRI) imaging, in 30 individuals with documented cardiac amyloidosis. We&#xD;
      will also enroll 15 individuals with recent myocardial infarction and 15 individuals with&#xD;
      hypertrophic cardiomyopathy as positive controls for fibrosis, and we will enroll 5&#xD;
      individuals without cardiovascular disease to undergo [68Ga]CBP8 PET/MRI imaging as a healthy&#xD;
      control group.&#xD;
&#xD;
      The primary hypothesis of this study is that [68Ga]CBP8 will bind to interstitial collagen&#xD;
      and quantify myocardial fibrosis in patients with cardiac amyloidosis. We hypothesize that&#xD;
      [68Ga]CBP8 uptake will be greater in patients with cardiac amyloidosis, myocardial fibrosis,&#xD;
      and hypertrophic cardiomyopathy than in healthy controls. Secondly, we also hypothesize that&#xD;
      [68Ga]CBP8 activity more strongly correlates with standard MRI measures in patients with&#xD;
      recent myocardial infarction and hypertrophic cardiomyopathy (where extracellular expansion&#xD;
      is caused by myocardial fibrosis/collagen deposition) than in patients with cardiac&#xD;
      amyloidosis (where myocardial fibrosis is combined with infiltration).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [68Ga]CBP8 is a novel gallium-68 labeled positron emission tomography (PET) probe that&#xD;
      selectively binds collagen type I, which constitutes the majority of fibrotic tissue. In&#xD;
      pre-clinical mouse models, [68Ga]CBP8 had the sensitivity to detect pulmonary fibrosis even&#xD;
      at early stages and specificity for collagen uptake with low non-specific uptake in&#xD;
      background tissues and organs. In preliminary studies in humans with idiopathic pulmonary&#xD;
      fibrosis, patients tolerated [68Ga]CBP8 without adverse effects, and there was a strong&#xD;
      correspondence between high collagen tracer signal and fibrotic lung regions established by&#xD;
      chest computed tomography (CT) scan. [68Ga]CBP8 may be a valuable tool to detect and quantify&#xD;
      collagen in the heart. The investigators propose to test [68Ga]CBP8 in a pilot study to image&#xD;
      myocardial fibrosis in patients with cardiac amyloidosis.&#xD;
&#xD;
      Cardiac amyloidosis is characterized by myocardial interstitial infiltration by misfolded&#xD;
      amyloid fibrils. Infiltration leads to increased myocardial stiffness and heart failure. In&#xD;
      patients with cardiac amyloidosis, myocardial stiffness may also be caused by extracellular&#xD;
      collagen deposition in the myocardium. Collagen deposition (i.e. myocardial fibrosis) results&#xD;
      in adverse cardiac remodeling through similar mechanisms as amyloidosis and may potentiate&#xD;
      heart failure in patients with cardiac amyloidosis. Myocardial fibrosis can be mitigated or&#xD;
      prevented. In addition, therapies directed against amyloid fibrils also have differential&#xD;
      response rates in cardiac amyloidosis patients with or without coexistent fibrosis. Magnetic&#xD;
      resonance imaging (MRI) is an established method of measuring extracellular volume (ECV), a&#xD;
      reliable way of quantifying myocardial fibrosis in conditions where the primary reason for&#xD;
      ECV expansion is myocardial fibrosis. ECV may not be an optimal surrogate of myocardial&#xD;
      fibrosis in patients with cardiac amyloidosis, where ECV is already quite expanded due to&#xD;
      myocardial amyloid infiltration. Thus, a means of accurate, non-invasive quantitation of&#xD;
      myocardial fibrosis has the potential to significantly improve cardiac amyloidosis care.&#xD;
&#xD;
      This pilot study is designed to understand whether myocardial fibrosis can be measured using&#xD;
      a collagen 1 targeted radiotracer ([68Ga]CBP8). The investigators would like to study 15&#xD;
      patients with light-chain (AL) cardiac amyloidosis and 15 patients with transthyretin (ATTR)&#xD;
      cardiac amyloidosis to understand differences in radiotracer uptake, if any. The&#xD;
      investigators will also enroll 15 patients with recent myocardial infarction and 15 patients&#xD;
      with hypertrophic cardiomyopathy as positive controls for fibrosis and will enroll 5&#xD;
      individuals without cardiovascular disease as negative controls.&#xD;
&#xD;
      The aim of this proposed research study is, using simultaneous PET/MRI imaging, to determine&#xD;
      whether [68Ga]CBP8 uptake will accurately identify and quantify myocardial fibrosis in&#xD;
      patients with cardiac amyloidosis, recent myocardial infarction, and hypertrophic&#xD;
      cardiomyopathy. The aim of this study is also to correlate [68Ga]CBP8 PET uptake with&#xD;
      standard MRI measures in patients with cardiac amyloidosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Standardized Uptake Value (SUVmean) of [68Ga]CBP8 uptake in the heart</measure>
    <time_frame>1 day</time_frame>
    <description>Standardized uptake value (SUV) mean is defined as the mean [68Ga]CBP8 concentration measured within the left ventricular myocardium multiplied by the decay-corrected amount of injected [68Ga]CBP8 normalized to patient weight. We expect SUVmean will be greater in patients with cardiac amyloidosis and myocardial infarction compared with healthy control subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extracellular volume from clinically performed simultaneous cardiac MRI</measure>
    <time_frame>1 day</time_frame>
    <description>We will correlate [68Ga]CBP8 uptake with standard MRI extracellular volume (ECV) measures. We expect [68Ga]CBP8 activity to more strongly correlate with MRI in patients with myocardial infarction than cardiac amyloidosis.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>[68Ga]CBP8 PET/MRI Amyloid Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with documented cardiac amyloidosis will undergo [68Ga]CBP8 PET/MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[68Ga]CBP8 PET/MRI Recent Myocardial Infarction Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with recent myocardial infarction will undergo [68Ga]CBP8 PET/MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[68Ga]CBP8 PET/MRI Healthy Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals without documented cardiovascular disease will undergo [68Ga]CBP8 PET/MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[68Ga]CBP8 PET/MRI Hypertrophic Cardiomyopathy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with hypertrophic cardiomyopathy will undergo [68Ga]CBP8 PET/MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]CBP8 PET/MRI</intervention_name>
    <description>Simultaneous cardiac PET/MRI images will be obtained following injection of [68Ga]CBP8</description>
    <arm_group_label>[68Ga]CBP8 PET/MRI Amyloid Subjects</arm_group_label>
    <arm_group_label>[68Ga]CBP8 PET/MRI Healthy Controls</arm_group_label>
    <arm_group_label>[68Ga]CBP8 PET/MRI Hypertrophic Cardiomyopathy Subjects</arm_group_label>
    <arm_group_label>[68Ga]CBP8 PET/MRI Recent Myocardial Infarction Subjects</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for AL-amyloid subjects:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  AL-CA: Diagnosis of systemic light chain amyloidosis by standard criteria:&#xD;
             Immunofixation of serum, serum free light chain (FLC) assay, a biopsy of fat pad/bone&#xD;
             marrow, or organ biopsy, followed by typing of the light chain using&#xD;
             immunohistochemistry or immunogold assay with confirmation by mass spectroscopy as&#xD;
             needed AND&#xD;
&#xD;
               -  Proof of cardiac involvement by AL amyloidosis&#xD;
&#xD;
               -  Abnormal cardiac biomarkers: abnormal high sensitivity TnT 5th generation levels&#xD;
                  (&gt; 15 ng/L) or abnormal age-appropriate NT-proBNP (abnormal values: &lt; 50 years: &gt;&#xD;
                  450 pg/ml; 50-75 years: &gt; 900 pg/ml; &gt; 75 years: &gt; 1800 pg/ml) OR&#xD;
&#xD;
               -  Abnormal echocardiogram (wall thickness &gt; 12 mm in the absence of other causes of&#xD;
                  increased LV wall thickness) OR&#xD;
&#xD;
               -  Abnormal CMR (wall thickness &gt; 12 mm, extracellular volume &gt; 0.40 or typical CMR&#xD;
                  appearance of cardiac amyloidosis with difficulty nulling images and non-coronary&#xD;
                  distribution late gadolinium enhancement) OR&#xD;
&#xD;
               -  Positive endomyocardial biopsy&#xD;
&#xD;
        Inclusion Criteria for ATTR-amyloid subjects:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  ATTR-CA: Diagnosis of either wildtype or hereditary transthyretin cardiac amyloidosis&#xD;
             by standard criteria: Endomyocardial biopsy followed by typing of the transthyretin&#xD;
             amyloidosis using immunohistochemistry or immunogold assay with confirmation by mass&#xD;
             spectroscopy as needed&#xD;
&#xD;
               -  Extracardiac biopsy with typical cardiac imaging findings&#xD;
&#xD;
               -  Hereditary ATTR amyloidosis by genetic testing OR&#xD;
&#xD;
               -  Grade 2 or grade 3 myocardial uptake of 99mTc-PYP if AL amyloidosis is excluded&#xD;
&#xD;
        Inclusion Criteria for recent myocardial infarction subjects:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  Recent MI: Diagnosis of recent type 1 myocardial infarction by standard criteria&#xD;
&#xD;
               -  More than 6 weeks from diagnosis of MI but within 6 months&#xD;
&#xD;
               -  Imaging evidence of loss of viable myocardium or persistent regional wall motion&#xD;
                  abnormalities in a pattern consistent with an ischemic etiology in more than one&#xD;
                  segment&#xD;
&#xD;
        Inclusion Criteria for hypertrophic cardiomyopathy subjects:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy: Diagnosis of hypertrophic cardiomyopathy by standard&#xD;
             criteria&#xD;
&#xD;
          -  MRI evidence of late gadolinium enhancement&#xD;
&#xD;
        Inclusion Criteria for recent healthy control subjects:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  No known cardiac amyloidosis or recent myocardial infarction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dialysis&#xD;
&#xD;
          -  NYHA (New York Heart Association) Class IV&#xD;
&#xD;
          -  Acute myocardial infarction within 6 weeks&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  History of adverse events from or allergy to gadolinium contrast media&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Severe claustrophobia despite use of sedatives&#xD;
&#xD;
          -  Decompensated heart failure (unable to lie flat for 1 hour)&#xD;
&#xD;
          -  Concomitant clinically significant non-ischemic non-amyloid heart disease (valvular&#xD;
             heart disease or dilated cardiomyopathy)&#xD;
&#xD;
          -  Body weight over limit for MRI table (&gt;300 lbs)&#xD;
&#xD;
          -  Contraindications for MRI (including non-compatible cardiac implantable electronic&#xD;
             devices, drug infusion pumps, and metallic or electric implants)&#xD;
&#xD;
          -  Any other reason determined by the investigator to be unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharmila Dorbala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vaidehi Chemburkar, MS</last_name>
    <phone>617-732-6647</phone>
    <email>vchemburkar@bwh.harvard.edu</email>
  </overall_contact>
  <reference>
    <citation>Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available.</citation>
    <PMID>31161770</PMID>
  </reference>
  <reference>
    <citation>Desogere P, Tapias LF, Rietz TA, Rotile N, Blasi F, Day H, Elliott J, Fuchs BC, Lanuti M, Caravan P. Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. J Nucl Med. 2017 Dec;58(12):1991-1996. doi: 10.2967/jnumed.117.193532. Epub 2017 Jun 13.</citation>
    <PMID>28611243</PMID>
  </reference>
  <reference>
    <citation>Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696.</citation>
    <PMID>28381537</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Sharmila Dorbala</investigator_full_name>
    <investigator_title>Director of Nuclear Cardiology</investigator_title>
  </responsible_party>
  <keyword>Amyloidosis</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Heart</keyword>
  <keyword>Imaging</keyword>
  <keyword>Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

